No HOPE without proof: do ARBs meet the standard for cardiovascular protection?

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Renin-angiotensin system (RAS) blockade is vital for cardiovascular disease (CVD) prevention.
• Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are key RAS blockers.
• The HOPE study confirmed ACE inhibitors' benefits beyond blood pressure reduction.

Purpose of the Study:

• To evaluate the efficacy of dual RAS blockade (ARB + ACE inhibitor) compared to monotherapy.
• To investigate the role of combination therapy in improving cardiovascular outcomes.
• To provide insights into RAS blockade interventions through the ONTARGET trial.

Main Methods:

• The ONTARGET trial compares high-dose ramipril (ACE inhibitor) with telmisartan (ARB) or a combination of both.
• This large-scale trial assesses cardiovascular morbidity and mortality.
• The study design allows for comparison of monotherapy versus dual blockade.

Main Results:

• Previous analyses show ARB- and ACE inhibitor-based regimens are comparable for stroke and heart failure.
• Emerging evidence suggests combination therapy may outperform monotherapy.
• ONTARGET results are anticipated to clarify the benefits of combined RAS blockade.

Conclusions:

• Dual blockade of the renin-angiotensin system warrants further investigation for enhanced cardiovascular protection.
• The ONTARGET trial is expected to yield significant data on combination RAS blockade therapy.
• Understanding the full potential of RAS blockade is critical for managing cardiovascular disease.